comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 22:41:56 - browse：45426

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The system is set up to fail children with medical complexity

WSS

Coercive sterilizations revealed by STAT prompt outrage

Curing rare childhood diseases will falter unless Congress steps up

Trans patients at the end of life deserve respect and dignity

Study: Spinal cord stimulation helps patients with paralysis walk again

Former Pear Therapeutics executives start new VC firm

Moderna says combo Covid

explore

comprehensive

focus

Psychedelics group wrestles with new pharma identity

Roche's accidental data boosts hopes for anti

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Wegovy improves function in certain heart failure patients

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA greenlights medical device to combat bladder issues

As demand for Covid shots wanes, Moderna seeks its next success

Study: Spinal cord stimulation helps patients with paralysis walk again

23andMe had bad news about my health. I wish a person had delivered it

Cheap, fast test for Zika and dengue could cost just $1

Wikipedia

'Essentially witchcraft:' A former naturopath takes on the field

Cigna wins case to block Amy Bricker's move to CVS

Health care court cases: Humana, Sutter, Novant

How faith leaders like me can help address America's obesity epidemic

Coercive sterilizations revealed by STAT prompt outrage

California store owner shot dead in dispute over displaying Pride flag: Police

hotspot

focus

entertainment

entertainment